Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Vaxfectin-adjuvanted seasonal influenza protein vaccine: correlation of systemic and local immunological markers with formulation parameters.

Shlapobersky M, Wei Q, Sullivan S, Vilalta A.

Vaccine. 2009 Oct 30;27(46):6404-10. doi: 10.1016/j.vaccine.2009.06.087. Epub 2009 Jul 14.

PMID:
19607952
2.

Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.

Hartikka J, Bozoukova V, Yang CK, Ye M, Rusalov D, Shlapobersky M, Vilalta A, Wei Q, Rolland A, Smith LR.

Vaccine. 2009 Oct 30;27(46):6399-403. doi: 10.1016/j.vaccine.2009.06.014. Epub 2009 Jun 21.

PMID:
19552895
3.

Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA.

Vilalta A, Shlapobersky M, Wei Q, Planchon R, Rolland A, Sullivan S.

Vaccine. 2009 Dec 9;27(52):7409-17. doi: 10.1016/j.vaccine.2009.08.075. Epub 2009 Sep 5.

PMID:
19735757
4.

Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines.

Smith LR, Wodal W, Crowe BA, Kerschbaum A, Bruehl P, Schwendinger MG, Savidis-Dacho H, Sullivan SM, Shlapobersky M, Hartikka J, Rolland A, Barrett PN, Kistner O.

Hum Vaccin Immunother. 2013 Jun;9(6):1333-45. doi: 10.4161/hv.24209. Epub 2013 Mar 6.

5.

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, Lalor P, Leamy V, Vahle R, Luke CJ, Rolland A, Kaslow DC, Smith LR.

Hum Vaccin. 2007 Sep-Oct;3(5):157-64. Epub 2007 Mar 20.

PMID:
17637571
6.

Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens.

Hartikka J, Bozoukova V, Ferrari M, Sukhu L, Enas J, Sawdey M, Wloch MK, Tonsky K, Norman J, Manthorpe M, Wheeler CJ.

Vaccine. 2001 Feb 28;19(15-16):1911-23.

PMID:
11228361
7.

Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.

Quintilio W, Kubrusly FS, Iourtov D, Miyaki C, Sakauchi MA, Lúcio F, Dias Sde C, Takata CS, Miyaji EN, Higashi HG, Leite LC, Raw I.

Vaccine. 2009 Jun 24;27(31):4219-24. doi: 10.1016/j.vaccine.2009.04.047. Epub 2009 May 5.

PMID:
19393709
8.

Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine.

Guy B, Pascal N, Françon A, Bonnin A, Gimenez S, Lafay-Vialon E, Trannoy E, Haensler J.

Vaccine. 2001 Feb 8;19(13-14):1794-805.

PMID:
11166905
9.

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.

Baldwin SL, Shaverdian N, Goto Y, Duthie MS, Raman VS, Evers T, Mompoint F, Vedvick TS, Bertholet S, Coler RN, Reed SG.

Vaccine. 2009 Oct 9;27(43):5956-63. doi: 10.1016/j.vaccine.2009.07.081. Epub 2009 Aug 11.

PMID:
19679214
10.

Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.

Okamoto S, Matsuura M, Akagi T, Akashi M, Tanimoto T, Ishikawa T, Takahashi M, Yamanishi K, Mori Y.

Vaccine. 2009 Sep 25;27(42):5896-905. doi: 10.1016/j.vaccine.2009.07.037. Epub 2009 Jul 31.

PMID:
19647814
11.

A novel emulsion adjuvant increases the immunogenic responses and protective efficacy of an inactivated influenza vaccine in BALB/c mice.

Wang S, Ke CW, Zou LR, Jing Z, Xie GX, Li X.

Intervirology. 2009;52(5):252-7. doi: 10.1159/000228927. Epub 2009 Jul 20.

12.

Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing.

Wee JL, Scheerlinck JP, Snibson KJ, Edwards S, Pearse M, Quinn C, Sutton P.

Mucosal Immunol. 2008 Nov;1(6):489-96. doi: 10.1038/mi.2008.59. Epub 2008 Sep 24. Erratum in: Mucosal Immunol. 2009 Mar;2(2):184.

PMID:
19079216
13.

The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice.

Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K.

Vaccine. 2008 Jun 25;26(27-28):3461-8. doi: 10.1016/j.vaccine.2008.04.029. Epub 2008 May 5.

PMID:
18495302
14.

Salivary gland delivery of pDNA-cationic lipoplexes elicits systemic immune responses.

Sankar V, Baccaglini L, Sawdey M, Wheeler CJ, Pillemer SR, Baum BJ, Atkinson JC.

Oral Dis. 2002 Nov;8(6):275-81.

PMID:
12477057
15.

Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®.

Doukas J, Morrow J, Bellinger D, Hilgert T, Martin T, Jones D, Mahajan R, Rusalov D, Sullivan S, Rolland A.

Vaccine. 2011 Jul 26;29(33):5443-52. doi: 10.1016/j.vaccine.2011.05.060. Epub 2011 Jun 17.

PMID:
21641955
16.

CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle.

Kovacs-Nolan J, Mapletoft JW, Latimer L, Babiuk LA, Hurk Sv.

Vaccine. 2009 Mar 23;27(14):2048-54. doi: 10.1016/j.vaccine.2009.01.117. Epub 2009 Feb 2.

PMID:
19428829
17.

The novel adjuvant CoVaccineHT increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro.

Bodewes R, Geelhoed-Mieras MM, Heldens JG, Glover J, Lambrecht BN, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

Vaccine. 2009 Nov 16;27(49):6833-9. doi: 10.1016/j.vaccine.2009.09.015. Epub 2009 Sep 17.

PMID:
19772942
18.

Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines.

Sullivan SM, Doukas J, Hartikka J, Smith L, Rolland A.

Expert Opin Drug Deliv. 2010 Dec;7(12):1433-46. doi: 10.1517/17425247.2010.538047. Review.

PMID:
21118032
19.

The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses.

Kayamuro H, Abe Y, Yoshioka Y, Katayama K, Nomura T, Yoshida T, Yamashita K, Yoshikawa T, Kawai Y, Mayumi T, Hiroi T, Itoh N, Nagano K, Kamada H, Tsunoda S, Tsutsumi Y.

Biomaterials. 2009 Oct;30(29):5869-76. doi: 10.1016/j.biomaterials.2009.07.009. Epub 2009 Jul 30.

PMID:
19646748
20.

Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.

Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW.

Int J Pharm. 2008 Dec 8;364(2):272-80. doi: 10.1016/j.ijpharm.2008.04.036. Epub 2008 Apr 30. Review.

PMID:
18555624

Supplemental Content

Support Center